Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 Jul;4(4):487–490. doi: 10.1128/cdli.4.4.487-490.1997

Production of polyclonal antibodies to feline tumor necrosis factor.

C M Otto 1, F Niagro 1, R A McGraw 1, C A Rawlings 1
PMCID: PMC170556  PMID: 9220170

Abstract

Two 13-amino-acid peptides were synthesized based on the putative feline tumor necrosis factor (FeTNF) sequence. The synthesized peptides were conjugated to keyhole limpet hemocyanin, emulsified in complete Freund's adjuvant, and injected into rabbits. The gene for FeTNF was cloned into the FLAG (International Biotechnologies Inc. [IBI], Kodak, New Haven, Conn.) fusion protein expression vector. The expressed fusion protein was purified by using the M-1 anti-FLAG octapeptide monoclonal antibody (IBI, Kodak). The fusion protein was emulsified in complete Freund's adjuvant and injected into chickens. The immune sera generated to the synthetic peptides and the fusion protein recognized the recombinant FeTNF fusion protein on Western or dot blot assay. The preimmune and immune sera were incubated with naturally occurring FeTNF (supernatants from lipopolysaccharide-stimulated cultured feline peritoneal exudate or peripheral mononuclear cells). The antibody raised to the recombinant FeTNF fusion protein and N-terminal synthetic peptide neutralized bioactivity of native FeTNF and recombinant human TNF. Preimmune sera did not have any neutralizing activity. The polyclonal antibodies were not specific for FeTNF, since both porcine and human recombinant TNF were neutralized by the fusion protein antibodies. The synthetic peptide antibodies recognized recombinant feline and equine TNF on a Western blot.

Full Text

The Full Text of this article is available as a PDF (94.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beutler B., Greenwald D., Hulmes J. D., Chang M., Pan Y. C., Mathison J., Ulevitch R., Cerami A. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985 Aug 8;316(6028):552–554. doi: 10.1038/316552a0. [DOI] [PubMed] [Google Scholar]
  2. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  3. Bringman T. S., Aggarwal B. B. Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. Hybridoma. 1987 Oct;6(5):489–507. doi: 10.1089/hyb.1987.6.489. [DOI] [PubMed] [Google Scholar]
  4. Cerami A. Inflammatory cytokines. Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S3–10. doi: 10.1016/0090-1229(92)90035-m. [DOI] [PubMed] [Google Scholar]
  5. Corti A., Fassina G., Marcucci F., Barbanti E., Cassani G. Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. Biochem J. 1992 Jun 15;284(Pt 3):905–910. doi: 10.1042/bj2840905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ellis J. A., Godson D., Campos M., Sileghem M., Babiuk L. A. Capture immunoassay for ruminant tumor necrosis factor-alpha: comparison with bioassay. Vet Immunol Immunopathol. 1993 Jan;35(3-4):289–300. doi: 10.1016/0165-2427(93)90040-b. [DOI] [PubMed] [Google Scholar]
  7. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986 Dec 4;95(1):99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar]
  8. Hirai M., Okamura N., Terano Y., Tsujimoto M., Nakazato H. Production and characterization of monoclonal antibodies to human tumor necrosis factor. J Immunol Methods. 1987 Jan 26;96(1):57–62. doi: 10.1016/0022-1759(87)90367-x. [DOI] [PubMed] [Google Scholar]
  9. Hopp T. P. Protein surface analysis. Methods for identifying antigenic determinants and other interaction sites. J Immunol Methods. 1986 Apr 3;88(1):1–18. doi: 10.1016/0022-1759(86)90045-1. [DOI] [PubMed] [Google Scholar]
  10. Horton R. M., Hunt H. D., Ho S. N., Pullen J. K., Pease L. R. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene. 1989 Apr 15;77(1):61–68. doi: 10.1016/0378-1119(89)90359-4. [DOI] [PubMed] [Google Scholar]
  11. Jones E. Y., Stuart D. I., Walker N. P. Crystal structure of TNF. Immunol Ser. 1992;56:93–127. [PubMed] [Google Scholar]
  12. Jättelä M. Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab Invest. 1991 Jun;64(6):724–742. [PubMed] [Google Scholar]
  13. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  14. Lin K. H., Cheng S. Y. An efficient method to purify active eukaryotic proteins from the inclusion bodies in Escherichia coli. Biotechniques. 1991 Dec;11(6):748, 750, 752-3. [PubMed] [Google Scholar]
  15. McGraw R. A., Coffee B. W., Otto C. M., Drews R. T., Rawlings C. A. Gene sequence of feline tumor necrosis factor alpha. Nucleic Acids Res. 1990 Sep 25;18(18):5563–5563. doi: 10.1093/nar/18.18.5563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Otto C. M., Niagro F., Su X., Rawlings C. A. Expression of recombinant feline tumor necrosis factor is toxic to Escherichia coli. Clin Diagn Lab Immunol. 1995 Nov;2(6):740–746. doi: 10.1128/cdli.2.6.740-746.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rimstad E., Reubel G. H., Dean G. A., Higgins J., Pedersen N. C. Cloning, expression and characterization of biologically active feline tumour necrosis factor-alpha. Vet Immunol Immunopathol. 1995 Apr;45(3-4):297–310. doi: 10.1016/0165-2427(94)05345-S. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Riveau G. J., Audibert F. M. Synthetic peptide vaccines against pathogens and biological mediators. Trends Pharmacol Sci. 1990 May;11(5):194–198. doi: 10.1016/0165-6147(90)90114-n. [DOI] [PubMed] [Google Scholar]
  19. Sherry B. A., Gelin J., Fong Y., Marano M., Wei H., Cerami A., Lowry S. F., Lundholm K. G., Moldawer L. L. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J. 1989 Jun;3(8):1956–1962. doi: 10.1096/fasebj.3.8.2721856. [DOI] [PubMed] [Google Scholar]
  20. Silva A. T., Bayston K. F., Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Infect Dis. 1990 Aug;162(2):421–427. doi: 10.1093/infdis/162.2.421. [DOI] [PubMed] [Google Scholar]
  21. Socher S. H., Riemen M. W., Martinez D., Friedman A., Tai J., Quintero J. C., Garsky V., Oliff A. Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor. Proc Natl Acad Sci U S A. 1987 Dec;84(24):8829–8833. doi: 10.1073/pnas.84.24.8829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Su X., Morris D. D., Crowe N. A., Moore J. N., Fischer K. J., McGraw R. A. Equine tumor necrosis factor alpha: cloning and expression in Escherichia coli, generation of monoclonal antibodies, and development of a sensitive enzyme-linked immunosorbent assay. Hybridoma. 1992 Dec;11(6):715–727. doi: 10.1089/hyb.1992.11.715. [DOI] [PubMed] [Google Scholar]
  23. Su X., Prestwood A. K., McGraw R. A. Production of recombinant porcine tumor necrosis factor alpha in a novel E. coli expression system. Biotechniques. 1992 Nov;13(5):756–762. [PubMed] [Google Scholar]
  24. Su X., Prestwood A. K., Otto C. M., Prickett D., McGraw R. A. Monoclonal antibodies to porcine tumor necrosis factor alpha: development of an enzyme-linked immunosorbent assay. J Immunoassay. 1992;13(2):253–272. doi: 10.1080/15321819208021230. [DOI] [PubMed] [Google Scholar]
  25. Takahashi N., Brouckaert P., Fiers W. Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice. Cancer Res. 1991 May 1;51(9):2366–2372. [PubMed] [Google Scholar]
  26. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tracey K. J., Cerami A. Tumor necrosis factor and regulation of metabolism in infection: role of systemic versus tissue levels. Proc Soc Exp Biol Med. 1992 Jun;200(2):233–239. doi: 10.3181/00379727-200-43426. [DOI] [PubMed] [Google Scholar]
  28. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  29. Vandenabeele P., Declercq W., Vercammen D., Van de Craen M., Grooten J., Loetscher H., Brockhaus M., Lesslauer W., Fiers W. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med. 1992 Oct 1;176(4):1015–1024. doi: 10.1084/jem.176.4.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Walter G. Production and use of antibodies against synthetic peptides. J Immunol Methods. 1986 Apr 17;88(2):149–161. doi: 10.1016/0022-1759(86)90001-3. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES